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Summary
The increasing prevalence of diabetes mellitus has led to a growing number of chronic com-
plications including diabetic nephropathy (DN). In addition to its high prevalence, DN is asso-
ciated with high morbidity and mortality especially due to cardiovascular diseases. It is well 
established that genetic factors play a role in the pathogenesis of DN and genetically suscep-
tible individuals can develop it after being exposed to environmental factors. DN is probably a 
complex, polygenic disease. Two main strategies have been used to identify genes associated 
to DN: analysis of candidate genes, and more recently genome-wide scan. Great efforts have 
been made to identify these main genes, but results are still inconsistent with different genes 
associated to a small effect in specific populations. The identification of the main genes would 
allow the detection of those individuals at high risk for DN and better understanding of its pa-
thophysiology as well. Arq Bras Endocrinol Metab. 2010;54(3):253-61
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Sumário
A crescente elevação na prevalência do diabetes melito (DM) acarretou em um aumento de 
suas complicações crônicas, entre elas a nefropatia diabética (ND). Além da elevada prevalên-
cia, a ND está associada à importante morbidade e mortalidade, principalmente por doenças 
cardiovasculares. É notória a contribuição genética na patogênese da ND, em que, na presença 
de fatores ambientais propícios, aqueles indivíduos geneticamente predispostos desenvolve-
rão a doença. Trata-se de uma doença com provável transmissão genética do tipo poligênica 
e complexa. Duas estratégias principais têm sido utilizadas na busca dos genes associados à 
ND: a avaliação de genes candidatos e, mais recentemente, a utilização de genoma wide scan. 
Grande empenho tem sido realizado para identificar os principais genes associados à ND, mas 
os resultados ainda são heterogêneos com diferentes genes apresentando um efeito pequeno 
em populações específicas. A identificação dos principais genes permitiria prever os indivíduos 
de maior risco para o desenvolvimento da ND, além de possibilitar um melhor entendimento 
fisiopatológico da doença. Arq Bras Endocrinol Metab. 2010;54(3):253-61
Descritores
Nefropatia; diabetes melito; genética; predisposição genética
iNTroDuCTioN
D  iabetes mellitus (DM) is a set of metabolic di-sorders with different etiologies characterized by 
hyperglycemia resulting from defects in insulin secre-
tion and/or action. In 2000, 171 million cases of DM 
worldwide were estimated, and that number is expected 
to increase to 366 million cases in 2030 (1). Conco-
mitantly, the number of patients who develop chronic 
complications of DM including diabetic nephropathy 
(DN) has grown. 
Chronic kidney disease (CKD) is defined as renal 
damage characterized by structural or functional ab-
normalities of the kidneys or glomerular filtration rate 
(GFR) < 60 mL/min/1.73 m2, with or without renal 
damage, over a period of at least three months, regard-
less of its causes (2). DN is characterized by a set of dia-
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betic pathophysiological changes, which begin with glo-
merular hyperfiltration and renal hypertrophy, and then 
progress to proteinuria and GFR reduction. Based on 
the levels of urine albumin excretion, in a didactic man-
ner, DN has two phases: incipient nephropathy or the 
microalbuminuria phase with urine albumin excretion 
(UAE) ranging between 20-199 µg/min (or 30-300 
mg/24h); and, clinical nephropathy or the proteinuria 
phase with UAE > 199 µg/min (> 300 mg/24h) or 
proteinuria ≥ 500 mg/24h. Microalbuminuria is con-
sidered a risk factor for DN progression (3).
About 20% to 30% of patients with type 1 and type 2 
DM develop DN; however, a smaller proportion of pa-
tients with type 2 DM will progress to end-stage renal 
disease (ESRD). Due to its high prevalence, the majority 
of patients requiring dialysis are type 2 DM. DN is the 
most common cause of ESRD in several countries (4,5) 
but not all diabetic individuals will develop this compli-
cation. Those who do not develop DN in the first 15 
years after disease onset seem to be genetically protected 
(6). Many environmental factors have been established 
as contributing to the development of DN while the role 
of others has yet to be clearly understood (7). It is known 
that factors such as hyperglycemia, arterial hypertension 
and/or dyslipidemia play a role in the development of 
DN in genetically predisposed individuals only.
The rates of hospitalization for all causes are about 
three times higher in patients with CKD than in those 
who do not have the disease (8). According to Pagano 
and cols. (9), patients with type 2 DM with DN and pe-
ripheral arterial disease are 1.2 to 1.3 times more likely 
to be hospitalized (9). Besides its high disease burden, 
ESRD is associated with increased mortality, mainly due 
to cardiovascular causes (10). Reduced renal function is 
by itself an indicator of high mortality. Other concomi-
tant risk factors such as hypertension and autonomic 
neuropathy can contribute to cardiovascular diseases 
(10). Even patients with DN initially characterized by 
microalbuminuria already have an increased risk for car-
diovascular diseases and higher mortality (11). Accord-
ing to accumulating evidence the risk of developing 
DN and cardiovascular disease starts when UAE values 
are still within normal ranges (12). Some authors con-
sider albuminuria a major risk factor for cardiovascular 
events rather than just a simple marker of DN progres-
sion (13) as some patients develop fatal cardiovascular 
events even before showing reduced renal function. In 
the metropolitan area of Porto Alegre, southern Brazil, 
25% of new patients require dialysis due to DM, and 
they show a high mortality rate during the first two 
years on dialysis (14).
It has not yet been clearly established by which 
mechanism some diabetic patients will progress to-
wards loss of renal function and require dialysis while 
others will maintain normal renal function. Research 
has focused on seeking potential genetic alterations as-
sociated to CKD and ESRD. In fact, genetic evidence 
has been found in case-control association and linkage 
studies, and more recently using genome-wide scan 
(GWS). These studies support the assumption that on-
set, progression, and severity of DN can be in part at-
tributed to genetic factors (15). 
The identification of genes associated with DN will 
allow recognizing those individuals who are at high 
risk of developing this complication. It will also allow a 
better understanding of the mechanisms and progress 
of DN. Earlier and more aggressive therapies could be 
provided to high-risk individuals and thus reduce the 
associated high disease burden and mortality. Advances 
in pharmacogenetic research may help treatment choic-
es by selecting renoprotective drugs according to indi-
vidual haplotypes (16).
The present review discusses the main information 
available in literature that reaffirms the importance of 
genetic factors in DN. Some findings of our recent ge-
netic studies are also summarized. 
GENETiC TraNSmiSSioN moDELS 
The genetic transmission mode of DN is still controver-
sial. Theoretically, as in other diseases, it might occur in 
three distinct forms, which would lead to the develop-
ment of DN (6,17).
Monogenic form: mutations in a gene with a domi-
nant role. 
Oligogenic form: mutations/polymorphisms in a 
few genes would contribute in an independent and cu-
mulative manner to increase susceptibility. 
Polygenic form: alterations in many DNA loci, and 
each would have a small and cumulative effect on DN 
development. 
Considering that DN is a multifactorial disease, the 
mode of transmission is likely to be polygenic, and ge-
netic interaction with other environmental factors and 
clinical data such as duration of the DM, arterial hyper-
tension, dyslipidemia, smoking would lead to the de-
velopment of DN. Familial aggregation studies do not 
allow to clearly establish a mode of transmission but 
they provide evidence supporting that this is a polygen-
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ic complex disease (6,17). On the other hand, studies 
using segregation analysis (18,19) suggest that familial 
aggregation of DN is due mainly to the action of a main 
genetic locus. This effect would be consistent with a 
monogenic or oligogenic form where few genes would 
have greater effect on the phenotype.
Since several genes may be involved in the devel-
opment of DN and many of them have not yet been 
identified, it is not possible to be completely sure about 
the exact heritability pattern in most cases.
STraTEGiES For iDENTiFiCaTioN oF GENES 
aSSoCiaTED WiTH DiaBETiC NEPHroPaTHy
Genes that confer susceptibility to DN can be sought in 
different ways. A widely established method is the can-
didate gene approach. The search for candidate genes 
includes the study of polymorphisms in one or more 
genes potentially involved in the pathogenesis of the 
disease. This approach is useful even when the influence 
of a gene on disease development is small (17).
Candidate genes are often analyzed in case-con-
trol studies by comparing the frequency of polymor-
phisms/mutations in candidate genes among patients 
with and without the disease. This is an appropriate 
study for investigating complex genetic transmission, 
and it is especially useful in situations where the genetic 
influence is relatively low and disease-related alleles are 
common in a population (17). However, this approach 
is very sensitive to population stratification, which may 
lead to spurious associations. In the light of that it has 
been proposed that these studies should include a large 
sample to obtain very small p-values and be based on 
well-established a priori assumptions. This approach 
has allowed to describing many polymorphisms associ-
ated with DN; however, the study results have been 
inconsistent. One of the most studied alterations is 
insertion/deletion on the angiotensin-converting en-
zyme (ACE) gene. A meta-analysis has shown that the 
D allele is associated with high risk of DN (20).
Another approach used to analyze candidate genes 
is the transmission disequilibrium test (TDT). This ap-
proach is not influenced by population stratification, but 
information is required about the individuals studied and 
their parents, and only heterozygote parents are informa-
tive. The frequency of transmission of risk allele is com-
pared to the expected 50%. Its main limitation is having 
access to the individual and his/her parents, especially 
for type 2 DM that has a late onset in life. In a case-con-
trol study we demonstrated that the ectoenzyme nucleo-
tide pyrophosphate phosphodiesterase (ENPP1) gene is 
associated with early development of ERSD in patients 
with type 1 DM (21), and using the TDT approach we 
confirmed this association was not due to population 
stratification (21). Araki and cols. (22) used the same ap-
proach to demonstrate that the APOE-epsilon 2 allele is 
associated with DN in type 1 diabetic individuals (22).
More recently candidate genes are being tested in 
prospective studies. This study design is less prone to 
survival bias than case control-studies but they are ex-
pensive and time-consuming. Alternatively, the authors 
are studying cohorts that have been followed up over a 
long period of time (23). The limitation of these stud-
ies is that they are not specifically designed to address a 
genetic effect of a specific gene. 
The use of microarrays has enabled fast, accurate anal-
ysis of a large number of candidate genes and to perform 
GWS based on single nucleotide polymorphisms (SNPs). 
GWS can identify chromosomal regions that contain 
genes potentially involved in the genesis of a disease 
under study. Panels of microsatellite markers or SNPs, 
at ~10 centimorgans (cM) intervals throughout the ge-
nome, are genotyped in several generations of families of 
patients with DM, affected or not with DN. The markers 
that most commonly occur in family members affected 
with DN indicate the location of a functional variant as-
sociated with the disease and is in linkage disequilibrium 
with the marker. Given the difficulty of finding large 
families with several members affected by DN, an alter-
native approach is to compare the observed and expected 
frequency of the markers in pairs of diabetic siblings con-
cordant and discordant for DN. A major advantage over 
the candidate gene approach is that this approach can 
detect chromosomal regions containing genes that were 
not previously known to be implicated in the pathogen-
esis of DN. However, it has the disadvantage of only de-
tecting genes that have a moderate or large effect (24). 
Using GWS we identified three polymorphisms located 
on chromosomes 9q and 11p associated with DN in two 
different populations of patients with type 1 DM (25).
EViDENCE For GENETiC PrEDiSPoSiTioN To 
DiaBETiC NEPHroPaTHy
Familial aggregation of diabetic nephropathy 
Studies of familial aggregation have showed that some 
families are predisposed to DN (26-28). Studies on sib-
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lings with type 1 or type 2 DM have reported that DN in 
one of the siblings is associated with around a 3- to 4-fold 
increase in the risk of DN in the other sibling (29,30). 
There appears to be a genetic inheritance contribut-
ing to the development of CKD. Forsblom and cols. (31) 
showed that the heritability (h2) of UAE rate is ap-
proximately 30% when analyzing non-diabetic children 
of type 2 diabetic individuals (31). This finding was 
corroborated by another study, which found that after 
adjustment for covariables such as sex, age, obesity and 
DM, approximately 30% of the variability of albumin-
creatinine rate was due to genetic factors (32).
The magnitude of the familial association cannot be 
attributed only to exposure to similar risk factors, sug-
gesting there is a genetic component (33).
Genes associated with diabetic nephropathy and 
different phenotypes 
although proteinuria and loss of renal function often 
occur concomitantly, there is evidence of different ge-
netic predispositions for each condition (15). This can 
explain why some patients may have persistent protein-
uria without progressing to loss of renal function (34) 
and other patients have loss of renal function without 
proteinuria or microalbuminuria (15,35). 
In genetic association studies, it is very important to 
clearly define the phenotype of interest. Most studies 
on heritability use albuminuria or proteinuria as a DN 
marker. In fact, loss of renal function measured by GFR 
is strongly associated with increased UAE. However, it 
is important to point out that a significant proportion 
of patients with DM develop loss of renal function but 
they maintain normoalbuminuria (35-37) and, con-
versely, some patients with clinical proteinuria maintain 
a stable GFR over the years (38).
UAE and GFR reduction are both genetically deter-
mined, but apparently independently (15). Langefeld 
and cols. (39) evaluated 310 families comprising 662 
patients with type 2 DM and found an h2 of 0.35 for 
UAE, and of 0.69 for GFR (39). These findings were 
similar to those described in other studies reporting an 
h2 of creatinine depuration of 0.63 among mono- and 
dizygotic twins (40). 
Studies of candidate genes 
One approach to identify genes associated to DN is the 
study of candidate genes. There are many studies of 
candidate genes for DN but the results are inconsistent 
(Table 1). The choice of the gene to be studied depends 
on knowledge concerning its actions in DN pathophys-
iology such as those involving blood pressure control, 
severity of proteinuria or insulin resistance (41). Below 
we present our experience with this approach.
Type 2 DM patients with microalbuminuria have 
high serum levels of circulating fatty acids (50) com-
pared to normoalbuminuric patients. Intestinal ab-
sorption of long-chain fatty acids is controlled by the 
intestinal fatty acid-binding protein 2 (FABP2). Thus, 
alterations in the gene that codifies the FABP2 can 
be candidates indicating predisposition to DN. A54T 
polymorphism (rs1799883) in FABP2 is associated 
with altered protein conformation, leading to greater 
affinity of the FABP2 protein for intestinal fatty acids 
with consequent serum increase. We genotyped this 
polymorphism in 1,042 Brazilian patients with type 2 
DM. An association of the T allele was found at dif-
ferent stages of DN (Figure 1) (48). This association 
was replicated in an independent sample of 483 white 
American subjects with type 2 DM (48).
Several studies analyzed the insertion/deletion 
(I/D) polymorphism in the ACE gene but the results 
about its association with DN in patients with type 1 and 
type 2 DM were inconsistent, possibly due to ethnic dif-
ferences of the populations studied (20). Besides, several 
studies used longer duration of DM as an inclusion cri-
terion, which might predispose to survival bias, insofar 
as the possible genes associated with DN could also be 
associated with increased mortality. Therefore, we chose 
to investigate a potential association between I/D poly-
morphism in the ACE gene and the development of DN 
in 982 Brazilian patients with type 2 DM, taking into 
account the duration of their disease. In patients with 
10 years or less of disease, having an allele D (DD/ID) 
resulted in an odds ratio (OR) of 2.66 (95% CI 1.12-
6.58, p = 0.015) for incipient DN and 3.19 (95% CI 
1.18-9.30, p = 0.012) for overt DN. On the other hand, 
in patients with longer disease duration no increased risk 
for DN was seen associated with allele D (45).
Gene candidates for insulin resistance can also be 
considered DN candidates since insulin resistance is 
a common characteristic of patients with type 1 and 
type 2 DM who present increased UAE (51,52). The 
polymorphism in the ENPP1 gene, previously known 
as PC-1, was found to be associated with insulin resis-
tance (53). Based on this finding, a case-control study 
was conducted to assess the association between ad-
vanced DN and K121Q polymorphism (rs1805101) 
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Table 1. Candidate genes for diabetic nephropathy
author Gene Polymorphism or (95% Ci) p-value Case definitions
Canani and cols., 2002 (21) ENPP1/PC-1 K121Q (rs1805101) 2.3 (1.2-4.4) 0.014 Patients with type 1 DM with ESRD 
Leitao and cols., 2008 (42) ENPP1/PC-1 K121Q (rs1805101) 1.06 (0.73-1.54) 0.830 Type 2 DM with micro- or macroalbuminuria 
Ng and cols., 2002 (43)
 
GLUT1
 
XbaI
enhancer-2
1.83 (1.01-3.33)
2.38 (1.16-4.90)
0.044
0.036
Patients with type 1 DM with persistent 
proteinuria or ESRD
Santos and cols., 2006 (44) CATALASE -262C/T (rs35448603) 0.92 (0.63-1.37) 0.776 White patients with type 2 DM with micro- or 
macroalbuminuria or ESRD
Canani and cols., 2005 (45)
 
ACE
 
Ins/Del polymorphism 2.66 (1.12-6.58)
3.19 (1.18-9.30)
0.015
0.012
Type 2 DM with less than 24 years of disease:
incipient and overt DN, respectively 
Santos and cols., 2005 (46) CYBA p22phox C242T (rs4673) 2.24 (1.15-4.37) 0.045 White patients with type 2 DM, smokers, with 
micro- or macroalbuminuria or ESRD
Santos and cols., 2005 (47) RAGE -429C (rs1800625)
-374A (rs1800624)
1.31 (0.62-2.76)
0.77 (0.40-1.45)
0.720
0.270
703 Brazilians with type 2 DM (520 Caucasians) 
and 183 of African ascendance with micro- or 
macroalbuminuria or ESRD 
Canani and cols., 2005 (48) FABP-2 A54T (rs1799883) 2.4 (1.1-5.4) 0.005 Type 2 DM with microalbuminuria or persistent 
proteinuria or ESRD
Caramori and cols., 2003 (49) PPARγ2 Pro12Ala (rs1801282) 0.465 (0.229-0.945) 0.034 Type 2 DM with CKD and normoalbuminuria 
CKD: Chronic kidney disease; DM: diabetes mellitus; DN: diabetic nephropathy; ESRD: end-stage renal disease; OR: odds ratio; CI: confidence interval.
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Figure 1. Odds ratio (♦) with 95% confidence intervals (dotted line) for the 
presence of A54T polymorphism in FABP2 at the different stages of renal 
involvement adjusted for diabetes duration, body mass index, arterial 
hypertension, HbA1c, and cholesterol levels. ESRD: end-stage renal disease.
in the ENPP1 gene of patients with type 1 DM. The 
proportion of patients with the variant Q was 21.5% in 
the control group, 31.5% in those with proteinuria, and 
32.2% in those with ESRD (p = 0.012). In a stratified 
analysis for DM duration (< 24 or ≥ 24 years of DM), 
the risk of early onset of ESRD for patients with the 
variant Q was 2.3 times greater than for those without 
the variant Q (95% CI 1.2-4.4) and it was not associ-
ated with late onset ESRD (21). This association was 
confirmed using TDT, which showed that this associa-
tion was not due to population stratification (21).
Polymorphisms in GLUT1 gene associated with DN 
were also examined. GLUT1 is a glucose transporter in 
the kidneys and it has been associated with early kidney 
alterations leading to proteinuria. We studied 230 con-
trols (patients with DM1, disease duration of at least 15 
years and normoalbuminuria), and 262 cases (151 pa-
tients with persistent proteinuria and 111 with ESRD). 
The homozygosis for the XbaI(-) allele was associated 
with a discrete increased risk for DN when compared 
to other genotypes combined [OR 1.83 (95% CI 1.01-
3.33)]. A significant difference in genotype distribution 
among cases and controls was seen for the enhancer-2 
SNP1 (p = 0.036). There was an excess of genotype AA 
among the cases (10.7%) compared to controls (4.8%). 
These homozygous individuals presented an increased 
risk for DN compared to AG and GG genotypes com-
bined [OR 2.38 (95% CI 1.16-4.90)] (43).
Other studies analyzed different genes and did not 
find an association with DN (Table 1). One of these 
studies showed that, when patients were stratified for 
smoking, allele T (p22phox C242T polymorphism; 
rs4673) was more frequently seen in smokers with 
ESRD or persistent proteinuria than in normoalbumin-
uric patients (43% vs. 32%; p = 0.045). The multiple 
logistic regression analysis confirmed that CT and TT 
genotypes were independently associated with a greater 
risk of overt DN among smokers (OR = 6.76; 95% CI 
1.83-25.02) (46).
Our experience with candidate genes allowed us to 
identifying some genes that can be related to the deve-
lopment and severity of DN. 
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Genome-wide scan studies 
Recent GWS studies have demonstrated chromosomal 
regions potentially associated with DN. Table 2 shows 
the studies using a GWS approach. In DN concordant 
Pima Indians, a potential association was seen between 
chromosome 7q and phenotype of DN. The area be-
tween two markers (D7S500 and D7S1804), in 144 
cM, showed the strongest association, with a LOD 
score of 2.04. Two other susceptibility loci were also 
found in chromosomes 20 (LOD score of 1.83) and 3 
(LOD score of 1.48) (54). 
Genes located in chromosomes 22q, 5q, and 7q 
might be involved in the determination of UAE severity 
in patients with and without DM (58). In a genome-
wide association study, regions in chromosomes 19 
and 2q were identified as associated with proteinuria 
and ESRD in patients with type 1 DM (60). A locus in 
chromosome 1q was associated with ESRD only, while 
a locus in chromosome 20p was associated with protein-
uria only (60). Two independent loci were identified in 
chromosome 3q, 59 cM from each other, one associ-
ated with proteinuria and the other with ESRD (60). 
A genome-wide association study with 360,000 
SNPs using the microarray Affymetrix 5.0 was recently 
conducted in two independent cohorts of Caucasians 
patients with type 1 DM (25). SNPs that were highly 
significant in the two cohorts were selected for further 
analyses. Eleven SNPs located at 4 loci were closely as-
sociated with DN (p < 1 x 10-5) (Table 3). Some of 
these associations found in the cross-sectional study 
were confirmed in a prospective sample of the Diabe-
tes Control and Complications Trial/Epidemiology of 
Diabetes Interventions and Complications (DCCT/
EDIC). Three of the 11 initial SNPs had their associa-
tion confirmed, two were borderline and the remaining 
did not show a significant association with the develop-
ment of DN (proteinuria or CKD) (25) (Table 4).
Other authors have reported an association of dif-
ferent chromosomal regions using GWS approach to 
search for DN related genes (Table 2) (55-57,59).
CoNCLuSioN aND PErSPECTiVES
In conclusion, clinical and epidemiological studies have 
evidenced a genetic component of DN. However, no 
specific gene has been able to explain most DN cases 
yet. The results of studies that identified genes or ge-
nome regions associated with DN were quite incon-
sistent. The lack of more consistent results is probably 
due to different factors. Most genetic studies have been 
performed in selected populations but they are hetero-
geneous between them. It should also be pointed out 
that an isolated candidate gene is sought when various 
genes are probably involved and possibly interlinked. 
Joint efforts are essential to achieve robust findings in 
the study of genetics of DN. In the light of remarkable 
Table 2. Genome-wide scan studies for genes associated with diabetic nephropathy
author Population studied regions associated Phenotype
Imperatore and cols., 1998 (54) Pima Indians- 98 siblings with DM2, concordant for ND 7q, 3 and 20 Albuminuria or proteinuria
Vardarli and cols., 2002 (55) 125 patients with DM2 18q22.3-23 Albuminuria
Tanaka and cols., 2003 (56) Japanese with DM2 grouped into cases (with DR and DN) and 
controls (with DR and without DN) 
16q13 Albuminuria
Bowden and cols., 2004 (57) 266 siblings with DM2, African-Americans, concordant for DN  3q, 7p and 18q CKD
Krolewski and cols., 2006 
(58)
59 Caucasian families, 1 African-American, and 3 
Hispanic. Members with and without DM2
22q, 5q and 7q Albuminuria
Iyengar and cols., 2007 (59)
 
1,227 subjects from 378 families with 
DM1 or DM2, concordant or discordant for DN
2q14.1, 7q21.1 and 15q26.3
7q21.3, 10p15.3, 14q23.1 and 18q22.3
Albuminuria 
Proteinuria or ESRD
Rogus and cols., 2008 (60)
 
 
Sibling concordant for DM1 and discordant for ND 19q, 2q and 3q
1q
20p
Proteinuria and ESRD
ESRD
Proteinuria 
Pezzolesi and cols., 2009 (25)
 
 
 
Type 1 DM patients with DN (cases) and without DN (controls)
 
 
7p - CPVL/CHN2
9q - locus FRMD3
 11p - locus CARS
 13q
Proteinuria and ESRD
 
 
 
CKD: Chronic kidney disease; DM: diabetes mellitus; DN: diabetic nephropathy; DR: diabetic retinopathy; ESRD: end-stage renal disease.
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Table 3. Single nucleotide polymorphisms associated with diabetic nephropathy in a population of  GoKinD
SNP Chromosome Position (mb) Nearest gene risk allele 
Frequencies of risk alleles for cases and controls 
GWu* GoKinD
 
 
JDC** GoKinD
Controls Cases p-value Controls Cases p-value
N         413 379     472 441  
rs39059 7p 29.2 CPVL/CHN2 A(G) 0.61 0.69 8.8 x 10-4   0.60 0.67 1.7 x 10-3
rs39075 7p 29.2 CPVL/CHN2 G(A) 0.57 0.66 2.0 x 10-4   0.57 0.64 8.2 x 10-4
rs1888747 9q 85.3 FRMD3 G(C) 0.68 0.73 3.6 x 10-3   0.66 0.74 4.4 x 10-5
rs10868025 9q 85.4 FRMD3 A(G) 0.59 0.66 1.9 x 10-3   0.56 0.66 7.2 x 10-5
rs739401 11p 3.0 CARS C(T) 0.46 0.54 4.7 x 10-4   0.49 0.55 3.6 x 10-3
rs451041 11p 3.0 CARS A(G) 0.46 0.54 6.9 x 10-4   0.48 0.56 1.3 x 10-3
rs1041466 13q 109.0 No gene G(A) 0.39 0.47 3.6 x 10-3   0.43 0.51 2.7 x 10-4
rs1411766/rs17412858 13q 109.1 No gene A(G) G(A) 0.31 0.39 8.5 x 10-4   0.32 0.40 6.4 x 10-4
rs6492208/rs2391777 13q 109.1 No gene T(C) G(A) 0.55 0.62 8.7 x 10-3   0.56 0.65 1.9 x 10-4
rs7989848 13q 109.1 No gene A(G) 0.49 0.56 2.0 x 10-3   0.50 0.57 1.1 x 10-3
rs9521445 13q 109.1 No gene A(C) 0.47 0.54 2.1 x 10-3   0.47 0.55 4.2 x 10-4
* GWU – George Washington University; 
** JDC – Joslin Diabetes Center.
Table 4. Single nucleotide polymorphisms associated with diabetic nephropathy in a population of DCCT/EDIC
SNP Chromosome Position (mb) Nearest gene risk allele allele frequency p-value (unicaudal) Hazard ratios
rs39075 7p 29.2 CPVL/CHN2 G 0.60 NS 0.85
rs1888746 9q 85.3 FRMD3 C 0.70 0.02 1.33
rs13289150 9q 85.4 FRMD3 A 0.62 0.05 1.23
rs451041 11p 3.0 CARS A 0.51 0.01 1.32
rs1041466 13q 109.0 No gene G 0.47 0.11 1.22
rs1411766 13q 109.1 No gene A 0.36 0.11 1.17
rs6492208 13q 109.1 No gene T 0.61 NS 0.90
rs7989848 13q 109.1 No gene A 0.53 NS 0.93
advances in this area of study, we hope that in the near 
future patients at high risk for developing DN could be 
identified and benefited with earlier specific therapies. 
We also expect to see a consequent reduction in disease 
burden and mortality due to this serious complication. 
New pharmacogenomic developments will contribute 
to better treatment choices for DN and, more impor-
tantly, will help preventing it based on an individual’s 
genetic characteristics. 
Disclosure: no potential conflict of interest relevant to this article 
was reported. 
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